Hong Kong’s Insilico Medicine has found a way to use AI and deep learning to design, synthesise and validate a novel drug candidate in 46 days – 15 times faster than the best pharma compani
GlaxoSmithKline has taken an option to license Ionis’ antisense medicines for people with chronic hepatitis B virus infection after supportive phase 2 trial results.
GlaxoSmithKline may have scored a major cancer trial win after its belantamab mafodotin hit targets in the pivotal DREAMM-2 trial in relapsed multiple myeloma.
Roche’s influential chief medical officer Sandra Horning is to retire at the end of the year, the company has confirmed, to be replaced by a high-flyer from rival Eli Lilly.
Pharming has bought a late-stage pipeline drug aimed at a rare disease of the immune system from Novartis for $20 million up front, plus other payments further down the line.